These findings, accordingly with those obtained in vitro, encourages us to think that combining FASN inhibitors with temsirolimus or pertuzumab could be one example of a potential combinatorial available in the clinical management of HER2-positive breast cancer patients who progressed to standard treatments. Here, ERBB2 is linked to breast carcinoma.